share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

CRISPR Therapeutics | 4：持股變動聲明-高管 Kulkarni Samarth
SEC announcement ·  03/13 05:49
牛牛AI助理已提取核心訊息
CRISPR Therapeutics AG's CEO, Samarth Kulkarni, engaged in a series of stock transactions from March 10 to March 12, 2024. Kulkarni acquired a total of 28,250 common shares through the exercise of derivative securities. Concurrently, he sold 14,385 shares in open market transactions. The sales occurred on March 11 and March 12, with prices ranging from $74.44 to $78.26 per share, resulting in a total market value of $1,108,263.04. Following these transactions, Kulkarni directly holds 208,122 shares of CRISPR Therapeutics. Additionally, he has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT. The transactions are reported as in progress.
CRISPR Therapeutics AG's CEO, Samarth Kulkarni, engaged in a series of stock transactions from March 10 to March 12, 2024. Kulkarni acquired a total of 28,250 common shares through the exercise of derivative securities. Concurrently, he sold 14,385 shares in open market transactions. The sales occurred on March 11 and March 12, with prices ranging from $74.44 to $78.26 per share, resulting in a total market value of $1,108,263.04. Following these transactions, Kulkarni directly holds 208,122 shares of CRISPR Therapeutics. Additionally, he has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT. The transactions are reported as in progress.
CRISPR Therapeutics AG的首席執行官薩瑪斯·庫爾卡尼在2024年3月10日至3月12日期間進行了一系列股票交易。庫爾卡尼通過行使衍生證券共收購了28,250股普通股。同時，他在公開市場交易中出售了14,385股股票。銷售發生在3月11日和3月12日，價格從每股74.44美元到78.26美元不等，總市值爲1,108,263.04美元。在這些交易之後，庫爾卡尼直接持有CRISPR Therapeutics的208,122股股份。此外，他通過庫爾卡尼2023年GRAT擁有20萬股股票的間接實益所有權。交易報告爲正在進行中。
CRISPR Therapeutics AG的首席執行官薩瑪斯·庫爾卡尼在2024年3月10日至3月12日期間進行了一系列股票交易。庫爾卡尼通過行使衍生證券共收購了28,250股普通股。同時，他在公開市場交易中出售了14,385股股票。銷售發生在3月11日和3月12日，價格從每股74.44美元到78.26美元不等，總市值爲1,108,263.04美元。在這些交易之後，庫爾卡尼直接持有CRISPR Therapeutics的208,122股股份。此外，他通過庫爾卡尼2023年GRAT擁有20萬股股票的間接實益所有權。交易報告爲正在進行中。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。